76 results
8-K
EX-1.1
PRAX
Praxis Precision Medicines Inc
29 Mar 24
Other Events
4:30pm
shall have received the opinion and negative assurance letter of Latham & Watkins LLP, counsel for the Company, dated as of such date, in the form … assurance letter of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C., counsel for the Underwriters in connection with the offer and sale of the Offered
424B5
PRAX
Praxis Precision Medicines Inc
29 Mar 24
Prospectus supplement for primary offering
4:29pm
of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information … to seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position
424B5
PRAX
Praxis Precision Medicines Inc
27 Mar 24
Prospectus supplement for primary offering
4:49pm
by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other … below. There can be no assurance the IRS or a court will not take a contrary position to the discussion below regarding the tax consequences
S-3
EX-1.2
PRAX
Praxis Precision Medicines Inc
5 Mar 24
Shelf registration
9:08am
and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance … (b)(i).
(vii) No Guarantee of Placement, Etc. The Company acknowledges and agrees that (A) there can be no assurance that the Agent
S-3
PRAX
Praxis Precision Medicines Inc
5 Mar 24
Shelf registration
9:08am
for, and can provide no assurance as to the reliability of, any other information that others may give you. We will not make an offer to sell these securities … and Jefferies take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide.
The information
8-K
lx6fr9w
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
8-K
EX-99.2
5yeerpkniit
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
8-K
EX-1.1
edfelee mnci
12 Jan 24
Other Events
5:23pm
424B5
s7f wd41s
12 Jan 24
Prospectus supplement for primary offering
5:20pm
424B5
t4xme6ikfeymng1
10 Jan 24
Prospectus supplement for primary offering
5:28pm
8-K
vww8yrvrl2sac 9kvl
10 Jan 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-1.1
dtp wa7yfeptd3r
7 Dec 23
Entry into a Material Definitive Agreement
5:23pm
424B5
32u5h6mtz7b38 v0bn
7 Dec 23
Prospectus supplement for primary offering
5:19pm